NextGen Sciences establishes new US office and appoints Cliff Turner as president of its US operations
NextGen Sciences has announced the opening of new US-based operations.
The new office, located in the Chicago area, will support the company's customer base and distributors in the USA, and drive sales in the USA market.
Leading the USA operations will be Cliff Turner, newly appointed as president of NextGen Sciences Inc, a wholly owned subsidiary of NextGen Sciences.
Commenting on his new position, Turner said: "NextGen Sciences has an enormous commercial opportunity in the US market.
"I intend to work closely with the UK team and the US distribution network to maximise sales as the company continues to grow.
"NextGen Sciences is in an exciting position, and I am extremely pleased to be joining the company".
With over 20 years experience in sales and business development management in the life science sector, Turner brings a wealth of industry knowledge to NextGen Sciences.
His experience includes working with companies focusing on drug discovery through to full-scale pharmaceutical production, genomics, pharmacogenomics, transcription profiling, proteomics, as well as molecular diagnostics.
Previously, he was director of sales and market development at Nanosphere, and has held roles of increasing responsibility in companies such as Affymetrix and Life Technologies, now a division of Invitrogen.
He gained his first degree in biology from University of Illinois, and his MS degree in immunology and microbial genetics from Northern Illinois University.
Cliff Turner will replace Andrew Creasey, who is stepping back from the position of president to pursue a new opportunity and will remain involved with NextGen Sciences in a consultative role.
"We are very pleased that Cliff Turner will be joining NextGen Sciences.
"He has a strong background in sales and business development, and will greatly enhance our operations in the USA.
"I would also like to take this opportunity to thank Andrew Creasey for his support and commitment in establishing NextGen Sciences in the USA market.
"Dr Creasey was instrumental to our first major sales in the USA, and I would like to thank him for all that he has done for the company in the last 18 months", Said Kevin Auton, chief executive officer NextGen Sciences.
